InflaRx (IFRX) to Release Quarterly Earnings on Thursday

Key Points

• InflaRx is set to announce its Q2 2025 earnings on August 7th, with analysts predicting a loss of ($0.24) per share and revenue of $0.02 million.
• The company's stock has seen a decline of 5.0%, currently trading at $0.86, significantly lower than its 12-month high of $2.82.
• Analysts have varied opinions on InflaRx's stock, with Oppenheimer lowering its price target from $6.00 to $3.00 while Cantor Fitzgerald set an overweight rating with a target of $10.00.

InflaRx (NASDAQ:IFRX - Get Free Report) is projected to announce its Q2 2025 earnings results before the market opens on Thursday, August 7th. Analysts expect the company to announce earnings of ($0.24) per share and revenue of $0.02 million for the quarter.

InflaRx (NASDAQ:IFRX - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.18) by $0.04. The company had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.03 million. On average, analysts expect InflaRx to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

InflaRx Price Performance

Shares of InflaRx stock traded up $0.00 during trading on Tuesday, reaching $0.89. 146,081 shares of the company traded hands, compared to its average volume of 408,088. InflaRx has a 1-year low of $0.71 and a 1-year high of $2.82. The company has a 50 day moving average price of $0.86 and a 200-day moving average price of $1.34. The firm has a market capitalization of $59.68 million, a PE ratio of -1.08 and a beta of 1.29.

Institutional Trading of InflaRx

An institutional investor recently bought a new position in InflaRx stock. Woodline Partners LP bought a new position in InflaRx N.V. (NASDAQ:IFRX - Free Report) in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 750,984 shares of the company's stock, valued at approximately $766,000. Woodline Partners LP owned approximately 1.12% of InflaRx at the end of the most recent reporting period. Institutional investors own 42.39% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. Oppenheimer decreased their price target on shares of InflaRx from $6.00 to $3.00 and set an "outperform" rating for the company in a research note on Thursday, May 29th. Cantor Fitzgerald assumed coverage on shares of InflaRx in a research note on Tuesday, April 29th. They set an "overweight" rating and a $10.00 price target for the company. Finally, Raymond James Financial lowered shares of InflaRx from a "strong-buy" rating to an "outperform" rating and set a $2.00 price target for the company. in a research note on Thursday, May 29th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, InflaRx has a consensus rating of "Buy" and a consensus price target of $6.60.

InflaRx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.